Gerard van Odijk has been an Advisor to EQT since 2013.
Gerard has a track record of over 25 years in the European healthcare industry. From 2006 until 2012, he served as President and CEO of Teva Pharmaceuticals Europe and was driving the numerous acquisitions in those years. Previously, Gerard’s international executive career has led to a variety of senior positions in GlaxoSmithKline (GSK).
Gerard has been Chairperson of the biotech start-ups Merus and Syntarga and also served as Non Executive Board Member on the Board of UDG Healthcare, Neurogen and Alvogen. He is currently member of the advisory board of the Dutch Medicine Agency and chairs the supervisory board of the Hub 4 Organoids foundation.
Gerard holds a medical degree from the State University of Utrecht.